257 related articles for article (PubMed ID: 25688782)
1. Association between the use of fondaparinux vs low-molecular-weight heparin and clinical outcomes in patients with non-ST-segment elevation myocardial infarction.
Szummer K; Oldgren J; Lindhagen L; Carrero JJ; Evans M; Spaak J; Edfors R; Jacobson SH; Andell P; Wallentin L; Jernberg T
JAMA; 2015 Feb; 313(7):707-16. PubMed ID: 25688782
[TBL] [Abstract][Full Text] [Related]
2. Impact of fondaparinux versus enoxaparin on in-hospital bleeding and 1-year death in non-ST-segment elevation myocardial infarction. FAST-MI (French Registry of Acute ST-elevation and non-ST-elevation Myocardial Infarction) 2010.
Puymirat E; Schiele F; Ennezat PV; Coste P; Collet JP; Bonnefoy-Cudraz E; Roul G; Richard P; Simon T; Danchin N
Eur Heart J Acute Cardiovasc Care; 2015 Jun; 4(3):211-9. PubMed ID: 25075006
[TBL] [Abstract][Full Text] [Related]
3. Comparison of bleeding complications and 3-year survival with low-molecular-weight heparin versus unfractionated heparin for acute myocardial infarction: the FAST-MI registry.
Puymirat É; Aissaoui N; Silvain J; Bonello L; Cuisset T; Motreff P; Bataille V; Durand E; Cottin Y; Simon T; Danchin N;
Arch Cardiovasc Dis; 2012; 105(6-7):347-54. PubMed ID: 22800719
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of venous thromboembolism prophylaxis with fondaparinux or low molecular weight heparin in a large cohort of consecutive patients undergoing major orthopaedic surgery - findings from the ORTHO-TEP registry.
Donath L; Lützner J; Werth S; Kuhlisch E; Hartmann A; Günther KP; Weiss N; Beyer-Westendorf J
Br J Clin Pharmacol; 2012 Dec; 74(6):947-58. PubMed ID: 22515679
[TBL] [Abstract][Full Text] [Related]
5. Comparison of bleeding complications and one-year survival of low molecular weight heparin versus unfractioned heparin for acute myocardial infarction in elderly patients. The FAST-MI registry.
Puymirat E; Aïssaoui N; Collet JP; Chaib A; Bonnet JL; Bataille V; Drouet E; Mulak G; Ferrières J; Blanchard D; Simon T; Danchin N
Int J Cardiol; 2013 Jun; 166(1):106-10. PubMed ID: 22078393
[TBL] [Abstract][Full Text] [Related]
6. Angiographic and clinical outcomes in patients receiving low-molecular-weight heparin versus unfractionated heparin in ST-elevation myocardial infarction treated with fibrinolytics in the CLARITY-TIMI 28 Trial.
Sabatine MS; Morrow DA; Montalescot G; Dellborg M; Leiva-Pons JL; Keltai M; Murphy SA; McCabe CH; Gibson CM; Cannon CP; Antman EM; Braunwald E;
Circulation; 2005 Dec; 112(25):3846-54. PubMed ID: 16291601
[TBL] [Abstract][Full Text] [Related]
7. Meta-analysis of venous thromboembolism prophylaxis in medically Ill patients.
Kanaan AO; Silva MA; Donovan JL; Roy T; Al-Homsi AS
Clin Ther; 2007 Nov; 29(11):2395-405. PubMed ID: 18158080
[TBL] [Abstract][Full Text] [Related]
8. Effects of fondaparinux on mortality and reinfarction in patients with acute ST-segment elevation myocardial infarction: the OASIS-6 randomized trial.
Yusuf S; Mehta SR; Chrolavicius S; Afzal R; Pogue J; Granger CB; Budaj A; Peters RJ; Bassand JP; Wallentin L; Joyner C; Fox KA;
JAMA; 2006 Apr; 295(13):1519-30. PubMed ID: 16537725
[TBL] [Abstract][Full Text] [Related]
9. Unfractionated and low-molecular-weight heparin as adjuncts to thrombolysis in aspirin-treated patients with ST-elevation acute myocardial infarction: a meta-analysis of the randomized trials.
Eikelboom JW; Quinlan DJ; Mehta SR; Turpie AG; Menown IB; Yusuf S
Circulation; 2005 Dec; 112(25):3855-67. PubMed ID: 16344381
[TBL] [Abstract][Full Text] [Related]
10. Warfarin, kidney dysfunction, and outcomes following acute myocardial infarction in patients with atrial fibrillation.
Carrero JJ; Evans M; Szummer K; Spaak J; Lindhagen L; Edfors R; Stenvinkel P; Jacobson SH; Jernberg T
JAMA; 2014 Mar; 311(9):919-28. PubMed ID: 24595776
[TBL] [Abstract][Full Text] [Related]
11. Interactions between heparins, glycoprotein IIb/IIIa antagonists, and coronary intervention. The Global Registry of Acute Coronary Events (GRACE).
Brieger D; Van de Werf F; Avezum A; Montalescot G; Kennelly BM; Granger CB; Goodman SG; Dabbous OH; Agnelli G;
Am Heart J; 2007 Jun; 153(6):960-9. PubMed ID: 17540196
[TBL] [Abstract][Full Text] [Related]
12. Low-dose vs standard-dose unfractionated heparin for percutaneous coronary intervention in acute coronary syndromes treated with fondaparinux: the FUTURA/OASIS-8 randomized trial.
; Steg PG; Jolly SS; Mehta SR; Afzal R; Xavier D; Rupprecht HJ; López-Sendón JL; Budaj A; Diaz R; Avezum A; Widimsky P; Rao SV; Chrolavicius S; Meeks B; Joyner C; Pogue J; Yusuf S
JAMA; 2010 Sep; 304(12):1339-49. PubMed ID: 20805623
[TBL] [Abstract][Full Text] [Related]
13. Use of unfractionated heparin and a low-molecular-weight heparin following thrombolytic therapy for acute ST-segment elevation myocardial infarction.
Wang XK; Zhang Y; Yang CM; Wang Y; Liu GY
Clin Drug Investig; 2006; 26(6):341-9. PubMed ID: 17163268
[TBL] [Abstract][Full Text] [Related]
14. [Comparison of therapeutic efficacy between fondaparinux and low molecular weight heparin for patients with acute coronary syndrome].
Wang QK; Guo M; Zhang YQ; Song Y
Zhongguo Wei Zhong Bing Ji Jiu Yi Xue; 2010 Oct; 22(10):628-31. PubMed ID: 20977850
[TBL] [Abstract][Full Text] [Related]
15. Antithrombotic therapy with fondaparinux in relation to interventional management strategy in patients with ST- and non-ST-segment elevation acute coronary syndromes: an individual patient-level combined analysis of the Fifth and Sixth Organization to Assess Strategies in Ischemic Syndromes (OASIS 5 and 6) randomized trials.
Mehta SR; Boden WE; Eikelboom JW; Flather M; Steg PG; Avezum A; Afzal R; Piegas LS; Faxon DP; Widimsky P; Budaj A; Chrolavicius S; Rupprecht HJ; Jolly S; Granger CB; Fox KA; Bassand JP; Yusuf S;
Circulation; 2008 Nov; 118(20):2038-46. PubMed ID: 18955665
[TBL] [Abstract][Full Text] [Related]
16. Effect of un-fractionated heparin and low molecular weight heparin on hospital mortality in patients with non ST elevation acute coronary syndrome (ACS).
Angkasuwapala K; Ratanasumawong K; Ngarmukos T; Kehasukcharoen W; Boonsom W; Kamsa-ard S
J Med Assoc Thai; 2007 Oct; 90 Suppl 1():109-14. PubMed ID: 18431893
[TBL] [Abstract][Full Text] [Related]
17. Effects of fondaparinux in patients with ST-segment elevation acute myocardial infarction not receiving reperfusion treatment.
Oldgren J; Wallentin L; Afzal R; Bassand JP; Budaj A; Chrolavicius S; Fox KA; Granger CB; Mehta SR; Pais P; Peters RJ; Xavier D; Zhu J; Yusuf S;
Eur Heart J; 2008 Feb; 29(3):315-23. PubMed ID: 18084015
[TBL] [Abstract][Full Text] [Related]
18. Fondaparinux in the management of patients with ST-elevation acute myocardial infarction.
Turpie AG
Vasc Health Risk Manag; 2006; 2(4):371-8. PubMed ID: 17323591
[TBL] [Abstract][Full Text] [Related]
19. Patterns of use of heparins in ACS. Correlates and hospital outcomes: the Global Registry of Acute Coronary Events (GRACE).
Klein W; Kraxner W; Hödl R; Steg PG; Budaj A; Gulba D; Sadiq I; van de Werf F; White K; Fox KA;
Thromb Haemost; 2003 Sep; 90(3):519-27. PubMed ID: 12958622
[TBL] [Abstract][Full Text] [Related]
20. Trends in use of anti-thrombotic agents and outcomes in patients with non-ST-segment elevation myocardial infarction (NSTEMI) managed with an invasive strategy.
Wayangankar SA; Roe MT; Chen AY; Gupta RS; Giugliano RP; Newby LK; de Lemos JA; Alexander KP; Sanborn TA; Saucedo JF
Indian Heart J; 2016; 68(4):464-72. PubMed ID: 27543467
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
